CYP19A1 and Arthralgia: A systematic review and meta-analysis reported prevalence rates of aromatase inhibitor-induced arthralgia ranging from 20% to 73.7% and a pooled prevalence estimate of 45.9% (95% CI: 0.397–0.520) [10].